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Abstract: Traditionally, anti-platelet autoantibodies accelerating platelet clearance from the 
peripheral  circulation  have  been  recognized  as  the  primary  pathopysiological  mechanism 
in  chronic  immune  thrombocytopenia  (ITP).  Recently,  increasing  evidence  supports  the 
co-existence of insufficient megakaryopoiesis. Inadequate low thrombopoietin (TPO) levels 
are associated with insufficient proliferation and differentiation of megakaryocytes, decreased 
proplatelet formation, and subsequent platelet release. Recently two novel activators of TPO 
receptors have been made available: romiplostim and eltrombopag. In several phase III studies, 
both agents demonstrated increase of platelet counts in about 80% of chronic ITP patients 
within 2 to 3 weeks. These agents substantially broaden the therapeutic options for patients with 
chronic ITP although long-term results are still pending. This review will provide an update 
on the current conception of underlying mechanisms in ITP and novel, pathophysiologically 
based treatment options.
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Immune thrombocytopenic purpura (ITP) is an autoimmune hematologic disorder 
characterized by low platelet count and bleeding. Recently, an international working 
group has suggested new definitions of the clinical phases of ITP. Chronic ITP regularly 
affects primarily adults with persistence of thrombocytopenia for .12 months.1 
Persistent ITP was suggested for patients with ITP up to 12 months after diagnosis, 
as spontaneous remissions still occur. In children, ITP is usually an acute disease with 
spontaneous remissions within a few days or weeks, virtually never lasting longer 
than half a year.
ITP can be separated, pathophysiologically, into a primary and a secondary form. In 
primary ITP no other disorder can be identified. Secondary forms of ITP are associated 
with various diseases such as infections (eg, hepatitis C, HIV or Helicobacter pylori), 
autoimmune disorders (eg, lupus erythematosus or antiphospholipid syndrome) and 
last but not least, malignancies (eg, chronic lymphatic leukemia or lymphomas). This 
review will focus on the recently recognized role of impaired megakaryopoiesis in 
patients with chronic ITP.
Symptoms and laboratory findings
The characteristic bleeding sites in ITP are petechiae and mucosal bleeding in the oral 
cavity, the gastrointestinal tract or the urinary tract. Most of these bleeding episodes are 
mild; in patients with persistently low platelet counts substantial   mortality is associated Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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with bleeding episodes and   infections.2 Patients presenting 
with thrombocytopenia due to ITP demonstrate typically 
isolated thrombocytopenia and an otherwise unremarkable 
peripheral smear as well as normal plasmatic coagulation. 
Other causes of thrombocytopenia have to be excluded. Taking 
a thorough history is essential for ruling out drug-induced 
thrombocytopenia (eg, heparins, quinine, trimethoprim-
sulfamethoxazole, ranitidine). A family history might give 
clues to rare types of inherited thrombocytopenia such as Ber-
nard-Soulier syndrome associated with giant platelets. Last 
but not least, pseudo thrombocytopenia must be excluded. 
A thorough work up is essential to detect underlying disorders 
associated with secondary immune thrombocytopenia.3 In 
patients with platelet counts .50,000/µL, diagnosis of ITP 
is usually made incidentally. Patients with platelet counts 
,50,000/µL may develop bleeding complications either 
spontaneously or after minor trauma. Patients with platelet 
counts of ,10,000 to 20,000/µL, especially elderly, are at 
high risk for severe bleeding complications including major 
bleeding to internal sites and spontaneous intracerebral 
hemorrhage.4 A bone marrow examination is usually not 
required as number of megacaryocytes can actually vary 
substantially and do not necessarily correlate with extent of 
thrombocytopenia. However, we recommend performing a 
bone marrow biopsy for treatment of refractory disease and 
in patients over 60 years owing to an increased incidence of 
myelodysplastic syndrome. Testing for antiplatelet antibod-
ies is usually not recommended. Antiplatelet autoantibodies 
are not pathognomonic for ITP and can be associated with 
other disorders such as viral hepatitis, B-cell lymphomas 
or myelodysplasia. Detection of platelet-bound antibodies 
does have an estimated positive predictive value of ∼80% t; 
a negative test result cannot rule out the diagnosis of ITP.5,6 
The predictive values for assays to test free plasma anti-
bodies are even lower. Up to 50% of ITP patients do not 
have detectable antiplatelet autoantibodies.7 Therefore the 
American Society of Hematology and a recently published 
international consensus report do not recommend antiplatelet 
autoantibody testing in patients with ITP.8,9
Autoantibody-dependent platelet 
destruction and impaired 
megakaryopoiesis
Physiologically, in response to a blood vessel injury, platelets 
adhere to the subendothelial matrix via von Willebrand 
factor, subsequently become activated and secrete tissue 
factor and other procoagulatory molecules. This first step 
of hemostasis essentially depends on platelet count and 
functionality.   Platelet counts of ,30,000/µL are associated 
with a substantially elevated bleeding risk. Autoantibodies 
against platelets antigens are detectable in ITP patients. 
However sensitivity (approx. 50%) and specificity (approx. 
70%) are low. Furthermore antiplatelet antibodies have 
been detected in non-ITP patients.10,11 IgG autoantibody 
coated platelets have a reduced life span.12 Macrophages 
and phagocytes in spleen and liver-expressing Fc-receptors 
are the effector cells of accelerated platelet clearance. The 
corresponding platelet antigens are primarily fibrinogen-
receptor (glycoprotein IIb/IIIa) and von Willebrand-
receptor (glycoprotein Ib/V/IX).13 Characteristically, these 
molecules are expressed at a high density on the platelet 
surface (up to 100,000 per platelet). However, antigens 
with a lower expression, such as glycoprotein-complexes 
Ia/IIa for collagen-receptor (∼1000/platelet) can also 
induce autoantibody formation.14 Moreover, phagocytosis 
of platelets by antigen-presenting cells yields neoantigens, 
resulting in sufficient antibody formation to cause throm-
bocytopenia. This mechanism may be a likely explanation 
for the observation, that in some patients no autoantibodies 
against common platelet – receptors are detectable.15 The 
autoantibody-producing cells are a limited number of B-cell 
derived clones with somatic mutations and antigen-driven 
affinity.7 These clones, however, require costimulatory sig-
nals from activated T-helper cells. Accordingly, increased 
numbers of HLA-DR+ T cells and decreased numbers of T 
regulatory cells are often observed in these patients.16,17
Autoantibody-mediated accelerated peripheral platelet 
destruction is not the only principle in the pathophysiology 
of chronic ITP. Ineffective thrombopoiesis has been 
recognized as another important underlying mechanism. 
Obviously, the very same autoantibodies directed against 
platelet glycoprotein Ib/V/IX and IIb/IIIa are also capable 
of inhibiting megakaryocyte growth. It was demonstrated 
in the 1980s that sera of patients with ITP actually inhibit 
megakaryocyte growth in culture, supporting the concept of 
suboptimal platelet production as a contributing factor to 
thrombocytopenia.18,19 Furthermore, thrombopoietin (TPO) 
levels in patients with ITP were only modestly increased 
compared to other thrombocytopenic disorders like 
amegakaryocytic thrombocytopenia or aplastic anemia with 
TPO levels up to 30-times higher, and thus are inadequately 
low.20–22 Physiologically, a negative feedback loop regulates 
megakaryocyte proliferation and formation of platelets. TPO 
is primarily produced in the liver and binds to membrane Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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receptors on platelets with a high affinity to be internalized 
thereafter.23,24 At high platelet counts, most of the circulating 
TPO is taken up by the platelets and little is left to bind 
to TPO receptors on megakaryocytes. If platelets are low, 
TPO serum levels are increased, just as observed in patients 
with amegakaryocytic thrombocytopenia. Surprisingly, 
considering the often extremely low platelet counts in ITP 
patients, TPO levels are only minimally and thus inadequately 
elevated.19,25 Similar to ITP in other disorders with platelet 
destruction such as thrombotic-thrombocytopenic purpura 
or hemolytic-uremic syndrome, TPO levels in these patients 
are also only moderately increased.26,27 Considering these 
principles, stimulation of megakaryopoiesis has been 
recognized to be a potentially effective treatment strategy to 
increase platelet counts in patients with chronic ITP.
Treatment of ITP
For treatment of chronic ITP, 3 different strategies based on 
pathopysiological mechanisms can be used: (1) increasing 
platelet production by stimulating thrombopoiesis; 
(2) increasing platelet survival by reducing phagocytosis by 
macrophagocytes via splenectomy, immunoglobulins or vinca 
loaded platelets; and (3) decreasing autoantibody production 
by immunosuppression.
Stimulating thrombopoiesis  
and platelet formation: steroids, 
romiplostim and eltrombopag
Patients without bleeding symptoms and platelet counts of 
.50,000/µL do not have an increased risk of spontaneous 
bleeding and should generally only be observed closely. In 
patients with platelet counts between 20,000 and 50,000/µL 
treatment decisions should be made individually considering 
age, comorbidity and concurrent medication. Even with these 
platelet counts, we usually do not recommend treatment 
for patients under 60 years of age in the absence of oral 
anticoagulation, recent surgery, uncontrolled hypertension, 
peptic ulcer disease or other disorders associated with an 
elevated bleeding risk.9 For patients with a bleeding history 
or ,20,000 platelets/µL a therapeutic intervention is usually 
warranted. Steroids are thought to increase platelet counts 
through their immunosuppressive action; however, recent 
data suggest that they may also work by increasing platelet 
production.28,29 Steroids are still considered to be the first line 
of therapy. A common prednisone regimen (1 mg/kg daily 
for 3 weeks) has response rates of approximately 60%.30,31 
Alternatively, a pulsed dexamethasone regimen (40 mg for 
4 days per month) results in a more rapid response (within 
2 to 4 days) but is associated with more side effects such as 
hyperglycemia, insomnia and edema.32
Unfortunately, despite high initial response rates, 
long-term remissions with glucocorticoids range only from 
10% to 30% for patients with chronic ITP.33,34 Considering 
the findings of suboptimal thrombopoietin levels, stimulating 
megakaryopoiesis via the TPO receptor seems a reasonable 
treatment approach. Several TPO receptor agonists have been 
developed, 2 of which have already shown efficacy in phase III 
trials and are licensed: romiplostim and eltrombopag.
Romiplostim is composed of 2 identical peptide 
sequences targeting the TPO receptor. The peptides are linked 
via polyglycine and covalently bound with 2 Fc-fragments 
to prolong their half-life in the circulation. Binding to TPO 
receptor with a high affinity induces megakaryocyte dif-
ferentiation via phosphorylation of JAK2 and STAT5. In 
clinical trials, romiplostim induced a dose-dependent increase 
in platelet counts, peaking 12 to 16 days after onset of treat-
ment. In a phase I trial 6 out of 8 healthy volunteers receiving 
2 to 10 µg/kg subcutaneously doubled their baseline platelet 
counts.35 The highest applied dose in this pilot study resulted 
in a nearly 6-fold rise in platelet counts after a single dose of 
romiplostim. Platelet counts were back close to the baseline 
by day 28 after drug application. Subcutaneous use did not 
differ from intravenous administration. The most commonly 
observed adverse reactions were moderate headache and a 
sore throat. A randomized pilot study in patients with ITP 
led to a dose-dependent increase of the platelet count to 
.50,000/µL in 12 out of 16 patients without significant 
adverse events.
Encouraged by these promising results, 2 placebo-
controlled randomized trials were initiated.36 42 splenec-
tomized and 41 non-splenectomized patients with ITP 
with ,30,000 platelets/µL received romiplostim sc once 
a week for a total of 24 weeks. Doses of study drug were 
adjusted to maintain platelet counts between 50,000 and 
200,000/µL. As controls, 21 ITP patients after splenectomy 
and 21 ITP patients without splenectomy were randomized 
to a placebo group. A durable response was achieved in 16 
of 42 splenectomized patients given romiplostim versus 
none of 21 given placebo (P = 0.0013), and in 25 of 41 
non-splenectomized patients given romiplostim versus 1 of 
21 given placebo (P , 0.0001). Moreover, in the treatment 
group, an overall response rate including transient response 
was achieved in 88% of non-splenectomized (36/41) and 
79% of splenectomized patients (33/42), respectively, Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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compared with 14% of non-splenectomized (3/21) and 0% 
splenectomized patients (0/21), respectively, given placebo 
(P , 0.0001). In the romiplostim group, platelet counts of 
50,000/µL were achieved by 25% of patients after 1 week 
and by 50% within 2 to 3 weeks. Forty-nine percent of 
romiplostim-treated patients and 2.4% of placebo-treated 
patients achieved a durable platelet response, defined as 
a platelet count 50,000/µL for .6 of the last 8 weeks of 
treatment. Interestingly, baseline TPO levels and response 
did not correlate. One patient experienced worsening of 
increased bone marrow reticulin after 7 weeks of treatment 
but returned to baseline 14 weeks after cessation of the 
drug. Thrombotic events were observed in 2 patients on 
romiplostim (popliteal artery thrombosis, cerebrovascular 
accident) and 1 on placebo (fatal pulmonary embolism). None 
of the patients developed antibodies against romiplostim or 
TPO. This study indicates that romiplostim seems to be safe 
and effective for patients with chronic ITP.
Another TPO-targeting agent is eltrombopag, a small 
non-peptide molecule that stimulates proliferation and 
differentiation of megacaryocytes via JAK2/STAT-signal-
ing pathway.37 This drug interacts with a transmembrane 
part of the TPO receptor. Eltrombopag is taken orally once 
daily. As its absorption can be significantly affected by 
food, it needs to be taken 2 hours before or after meals. 
Pharmacodynamics and pharmacokinetics are comparable 
to those observed with romiplostim, ie, after a median of 
8 days eltrombopaq induces a dose-dependent increase 
of platelet counts in healthy volunteers with a peak after 
16 days.38
A placebo-controlled trial evaluated eltrombopag 
in 118 adults with chronic ITP and platelet counts ,30,000 /µL 
at 3 dose levels (30, 50, and 75 mg, respectively).39 The primary 
end-point, a platelet count of .50,000/µL, was achieved in 
28%, 70%, and 81% of patients, respectively, and in only 11 
percent of patients in placebo group. By day 15, .80% of 
patients on 50 or 75 mg eltrombopag had an increased platelet 
count. The incidence and severity of adverse events were simi-
lar in the placebo and treatment group and consisted primarily 
of headache (placebo 21%, eltrombopag 15%). These results 
were confirmed in another phase III, placebo-controlled trial, 
including adult patients with chronic ITP and platelet counts 
of ,30,000/µL.40 Seventy-six patients received initially 50 
mg eltrombopag and subsequently 75 mg if platelet count 
did not reach 50,000/µL (ie, the primary endpoint) within 3 
weeks. After seven weeks 43 of 73 patients in the eltrombopag 
group (59%) and 6 of 37 patients in the placebo group (16%) 
had a response (P , 0.0001). There was no correlation of 
response rate to eltrombopag and   concomitant use of ITP 
drugs, splenectomy or number of   previous ITP treatments. 
Of 34 patients in the eltrombopag group who subsequently 
received a higher dose of eltrombopag, 10 (29%) successfully 
achieved .50,000 platelets/µL. Platelet counts generally 
returned to baseline values within 2 weeks after the end of 
treatment. Bleeding events were significantly reduced (39% 
vs 60%) in the eltrombopag group, whereas the frequency 
of adverse drug reactions was similar in both groups (each 
3%). Thus, efficacy and safety of eltrombopag seems to be 
comparable with that of romiplostim.
Despite these promising results, there are still considerable 
concerns about TPO receptor agonists. First, cessation of 
drug results in a rapid decline of platelet counts back to 
baseline, and thus a continuous application is required. 
Second, time to response is 1 to 4 weeks, and therefore in 
case of emergency, treatment with TPO agonist alone is 
inadequate. Third, long-term effects of these drugs are still 
unknown. The significance of reticulin accumulation in 
bone marrow is unclear. It is possible that thrombopoietic 
agents inherently bear the risk for reticulin deposition. 
Another concern is that long-term intake of TPO agonists 
could contribute to carcinogenesis, as the neoplastic cells in 
many hematopoietic malignancies express TPO receptors.41 
Likewise, in 6 of 44 patients with myelodysplasia treated 
with romiplostim, a transient increase of peripheral blasts 
was seen. After cessation of TPO agonist this effect was 
reversible in all but 1 patient, who progressed to secondary 
acute myeloid leukemia.42
increasing platelet survival: splenectomy, 
immunoglobulins and vinca loaded 
platelets
The spleen is regarded as the main site for removal of 
autoantibody-coated platelets from the circulation. Treatment 
options include either splenectomy or suppression of 
macrophages by immunoglobulins, or vinca loaded platelets. 
Splenectomy is the only surgical treatment option for 
ITP. Macrophages within the spleen are the effecter cells 
mediating rapid platelet clearance from the circulation. 
Accordingly, splenectomy is effective in approximately 
85% of patients and durable responses necessitating no 
further treatment are seen in about two thirds of patients 
with ITP.43 Risk factors associated with an inferior outcome 
after splenectomy are refractory disease, advanced age, 
dominant hepatic platelet sequestration and secondary forms Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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of ITP.44–47 Laparoscopic procedures are, at least, as safe as 
open surgery.48 Recommending splenectomy remains an 
individual decision that requires consideration of patient 
risk factors as described above as well as anesthesia-related 
risks. In general, every patient should be vaccinated against 
Haemophilus type B, Pneumococcus and Meningococcus 
as prophylaxis against overwhelming bacterial sepsis.49 
To minimize surgical procedure-related complications, 
a preoperative rise of platelet count is often mandatory. 
Intravenous immune globulins (IVIG) blocking Fc-gamma 
receptors on macrophages remain the mainstay of therapy in 
this setting, resulting (in most patients) in a reliable increase 
of platelet counts within a few days, lasting sometimes for 
weeks to even months.50 In case of an acute major bleeding 
complication, IVIG can be used in combination with platelet 
transfusions or even activated factor VII. Another approach 
is the transfusion of vinca loaded platelets (VLP). Ex vivo 
complexing of vinca alkaloids to platelets is a hypothetically 
attractive means to target the chemotherapy to effecter phago-
cytes. Recently we, and others, have seen promising results 
in heavily pretreated ITP patients using a facilitated method 
of generating VLP.51
Reducing autoantibodies production  
by immunosuppression
Patients who fail to respond to the treatments described 
above might be candidates for monoclonal antibodies or 
immunosuppressive therapy. Depletion of B-lymphocytes 
by the anti-CD20 antibody rituximab in patients with 
chronic ITP results in response rates of up to 50% within 
1 or 2 months.52,53
Immunosuppressive drugs, such as azathioprine, 
mycophenolate mofetil and cyclophosphamide, mainly target 
T-lymphocytes. Remission rates vary and time to response 
can be months. Furthermore, potentially severe adverse 
events such as neutropenia, renal failure or hepatitis limit 
their use.54,55
In conclusion, pathopysiological cofactors beyond 
accelerated clearance of autoantibody-coated platelets have 
been recognized in patients with chronic ITP. Recently, 
increasing evidence highlights insufficient megakaryopoiesis 
to be a major contributor to disease manifestation in these 
patients. Therefore stimulating megakaryopoiesis with TPO 
agonists such as romiplostim and eltrombopag are promising 
new treatment options. Still, incorporation of these new 
agents into existing treatment algorithms remains a clinical 
challenge, especially since long-term results are still pending. 
Therefore, first-line treatment should still be corticosteroids. 
Patients failing those should be considered candidates for 
splenectomy. If contraindications against splenectomy are 
present, treatment with the thrombopoietin receptor agonists 
should be considered. Patients failing to these should be 
considered candidates for alternative immunosuppressive 
treatment.
Finally, two main questions need to be addressed for 
the long-term treatment with thrombopoietin receptor 
agonists: What is the significance of possible bone marrow 
fibrosis? Is there an increased incidence of myelodysplastic 
syndrome? Prospective studies are scheduled to answer 
these questions.
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